Effect of chronic wound exudates and MMP-2/-9 inhibitor on angiogenesis in vitro

Plastic and Reconstructive Surgery

Volumn 116, Issue 2, 2005, Pages 539-545

  Ulrich, Dietmar ^a,b   Lichtenegger, Franziska ^a,b   Unglaub, Frank ^a,b   Smeets, Ralf ^a,b   Pallua, Norbert ^a,b  

^a Aachen University of Technology ^*

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; GELATINASE INHIBITOR; MATRIX METALLOPROTEINASE 2 INHIBITOR; MATRIX METALLOPROTEINASE 9 INHIBITOR; SURAMIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BURN; CHRONIC DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; EXUDATE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MODEL; PRIORITY JOURNAL; RANK SUM TEST; SKIN GRAFT; ULCER; WOUND;

AGED; AGED, 80 AND OVER; CHRONIC DISEASE; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; POSTPHLEBITIC SYNDROME; VARICOSE ULCER;

EID: 23044499048     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.prs.0000173447.81513.7a     Document Type: Article

References (39)

1. Tonnesen, M. G., Feng, X., and Clark, R. A. Angiogenesis in wound healing. J. Investig. Dermatol. Symp. Proc. 5: 40, 2000.
2. Risau, W. Mechanisms of angiogenesis. Nature 386: 671, 1997.
3. Folkman, J. Angiogenesis and angiogenesis inhibition: An overview. EXS 79: 1, 1997.
4. Iruela-Arispe, M. L., and Dvorak, H. F. Angiogenesis: A dynamic balance of stimulators and inhibitors. Thromb. Haemost. 78: 672, 1997.
5. Parks, W. C. Matrix metalloproteinases in repair. Wound Repair Regen. 7: 4251, 1999.
6. Armstrong, D. G., and Jude, E. B. The role of matrix metalloproteinases in wound healing. J. Am. Podiatr. Med. Assoc. 92: 12, 2002.
7. Ravanti, L., and Kahari, V. M. Matrix metalloproteinases in wound repair. Int. J. Mol. Med. 6: 391, 2000.
8. Visse, R., and Nagase, H. Matrix metalloproteinases and tissue inhibitors of melalloproteinases: Structure, function, and biochemistry. Circ. Res. 92: 827, 2003.
9. Ulrich, D., Noah, E. M., von Heimburg, D., and Pallua, N. TIMP-1, MMP-2, MMP-9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma. Plast. Reconstr. Surg. 111: 1423, 2003.
10. Ulrich, D., Hrynyschyn, K., and Pallua, N. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease. Plast. Reconstr. Surg. 112: 1279, 2003.
11. Saito, S., Trovato, M., You, R. et al., Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase 1 in chronic venous insufficiency. J. Vasc. Surg. 34: 930, 2001.
12. Trengove, N.J., Stacey, M. C., Macauley, S., et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen. 7: 442, 1999.
13. Bullen, E. C., Longaker, M. T., Updike, D. L., Benton, R., Ladin, D., and Hou, Z. Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds. J. Invest. Dermatol. 104: 236, 1995.
14. Tarlton, J. F., Bailey, A. J., Crawford, E., Jones, D., Moore, K., and Harding, K. G. The prognostic value of markers of collagen remodeling in venous ulcers. Wound Repair Regen. 7: 347, 1999.
15. Yan, L., and Moses, M. A. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 21: 1104, 2001.
16. Stetler-Stevenson, W. G. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention. J. Clin. Invest. 103: 1237, 1999.
17. Schnaper, H. W., Grant, D. S., Stetler-Stevenson, W. G., Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J. Cell. Physiol. 156: 235, 1993.
18. Raza, S. L., and Cornelius, L. A. Matrix metalloproteinases: Pro-and anti-angiogenic activities. JID Symp. Proc. 5: 47, 2000.
19. Patterson, B. C., and Sang, Q. X. A. Angiostatin-converting enzyme activities of human matrilysin (MMP 7) and gelatinase B/type IV collagenase (MMP 9). J. Biol. Chem. 272: 28823, 1997.
20. Cornelius, L. A., Nehring, L. C., Harding, E., et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J. Immunol. 161: 6845, 1998.
21. O'Reilly, M., Boehm, T., Shing, N., et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277, 1997.
22. Drinkwater, S. L., Smith, A., Sawyer, B. M., and Burnand, K. G. Effect of ulcer exudates on in vitro angiogenesis. Br. J. Surg. 89: 709, 2002.
23. Bishop, E. T., Bell, G. T., Bloor, S., Broom, I. J., Hendry, N. F. K., and Wheatley, D. N. An in vitro model of angiogenesis: Basic features. Angiogenesis 3: 335, 1999.
24. Wysocki, A. B., Staiano-Coico, L., and Grinell, F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J. Invest. Dermatol. 101: 64, 1993.
25. Yager, D. R., Zhang, L.Y., Liang, H. X., Diegelmann, R. F., and Cohen, I. K. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J. Invest. Dermatol. 107: 743, 1996.
26. Rogers, A. A., Burnett, S., Moore, J. C., Shakespeare, P. G., and Chen, W. Y. J. Involvement of proteolytic enzymes, plasminogen activators and matrix metalloproteinases in the pathophysiology of pressure ulcers. Wound Repair Regen. 3: 273, 1995.
27. Haas, T. L., and Madri, J. A. Extracellular matrix-driven matrix metalloproteinase production in endothelial cells. Trends Cardiovasc. Med. 9: 70, 1999.
28. Zhu, W. H., Guo, X., Villaschi, S., and Nicosia, R. F. Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis. Lab. Invest. 80: 545, 2000.
29. Mignatti, P., and Rifkin, D. B. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 49: 117, 1996.
30. Montesano, R., Pepper, M. S., Mohle-Steinlein, U., et al. Increased proteolytic activity is responsible for the aberrant morphogenetic behaviour of endothelial cells expressing middle T oncogene. Cell 62: 435, 1990.
31. Pepper, M. S., Belin, D., Montesano, R. et al. Transforming growth factor-β1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J. Cell. Biol. 111: 743, 1990.
32. Itoh, T., Tanioka, M., Yoshida, H. et al. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58: 1048, 1998.
33. Forsyth, P. A., Wong, H., Laing, T. D., et al. Gelatinase A (MMP-2), gelatinase B (MMP-9), and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br. J. Cancer 79: 1828, 1999.
34. Vu, T. H., Shipley, J.M., Bergers, G., et al. MMP-9/gelaninase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93: 411, 1998.
35. Dong, Z., Kumar, R., Yang, X., and Fidler, I. J. Macrophage derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88: 801, 1977.
36. Ferreras, M., Felbor, U., Lenhard, T., Olsen, B. R., and Delaissé, J. M. Generation and degradation of human endostatin proteins by varies proteinases. FEBS Lett. 486: 247, 2000.
37. Merchan, J. R., Chan, B., Kale, S., Schnipper, L. E., and Sukhatme, V. P. In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. J. Natl. Cancer Inst. 95: 388, 2003.
38. Brooks, P. C., Silletti, S., von Schalscha, T. L., Friedlander, M., and Cheresh, D. A. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92: 391, 1998.
39. Silletti, S., Kessler, T., Goldberg, J., Boger, D. L., and Cheresh, D. A. Disruption of matrix metalloproteinase 2 binding to integrin αvβ3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc. Natl. Acad. Sci. U.S.A. 98: 119, 2001.